Article

Pharmacologic decoupling of IRBC activation from anabolic collapse redefines ribosome biogenesis inhibition as a selective tumor suppressive strategy

2026-08-27

Abstract excerpt

Ribosome biogenesis (Ri-Bi) is widely targeted in cancer therapy, yet its inhibition is generally viewed as a broadly anti-anabolic intervention. In colorectal cancer, frontline treatments such as FOLFOX partly disrupt Ri-Bi, eliciting two biologically distinct outputs: an early p53-dependent checkpoint activation, known as the impaired ribosome biogenesis checkpoint (IRBC), and a later global anti-anabolic collap...

Topics

Open a Topic to create a Post that cites this publication.

Uncategorized literature

Identifiers and source

Literature Corpus work: d903d62a-438e-5765-8c45-55b85448179b
DOI: 10.64898/2026.08.24.744089

Open publication

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Click a neighbor to travelStep 1 · 12 closest

Pharmacologic decoupling of IRBC activation from anabolic collapse redefines ribosome biogenesis inhibition as a selective tumor suppressive strategyDOI 10.64898/2026.08.24.744089Read

Loss of <i>UBP1</i> drives oxaliplatin resistance through a targetable dependency on translation initiationSemantic proximity Read

Ribosome biogenesis as a potential therapeutic target in KRAS mutant colorectal cancer.Semantic proximity Read

An RNA damage response network mediates the lethality of 5-FU in colorectal cancerSemantic proximity Read

Dysregulated Ribosome Biogenesis Reveals Therapeutic Liabilities in Cancer.Semantic proximity Read

The novel RNA polymerase I transcription inhibitor PMR-116 exploits a critical therapeutic vulnerability in a broad-spectrum of high <i>MYC</i> malignanciesSemantic proximity Read

Ribosome Biogenesis Alterations in Colorectal CancerSemantic proximity Read

p53 at the crossroad of DNA replication and ribosome biogenesis stress pathwaysSemantic proximity Read

A second-generation eIF4A RNA helicase inhibitor exploits translational reprogramming as a vulnerability in triple-negative breast cancerSemantic proximity Read

Ribosomopathies and cancer: pharmacological implicationsSemantic proximity Read

Targeting Ribosome Biogenesis as a Novel Therapeutic Approach to Overcome EMT-related Chemoresistance in Breast CancerSemantic proximity Read

SLFN11-mediated ribosome biogenesis impairment induces TP53-independent apoptosisSemantic proximity Read

Driver mutations of the adenoma-carcinoma sequence govern the intestinal epithelial global translational capacity.Semantic proximity Read